Development of a myeloproliferative disorder in a patient with monoclonal gammopathy of undetermined significance secreting immunoglobulin of the M class and treated with thalidomide and anti-CD20 monoclonal antibody [4]

Blood

Volumn 97, Issue 8, 2001, Pages 2527-2528

  Kyrtsonis, M C ^a   Kokoris, S I ^a   Kontopidou, F N ^a   Siakantaris, M P ^a   Kittas, C ^a   Pangalis, G A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; THALIDOMIDE;

AGED; CASE REPORT; DISEASE COURSE; HUMAN; IMMUNOGLOBULIN PRODUCTION; LETTER; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; THROMBOCYTOSIS;

EID: 0035871782     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.8.2527     Document Type: Letter

References (4)

1. Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia
2. Antitumor activity of thalidomide in refractory multiple myeloma
3. Thalidomide is an effective agent for patients with primary amyloidosis
4. Pilot studies of thalidomide in acute myelogenous leukemia, myelodysplastic syndromes and myeloproliferative disorders